anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To obtain a cosmetic having preventing effects on dandruff and falling hair, promoting effects on hair production and removing effects on stain of skin, comprising an extract prepared by extracting aloe and components of Japanese angelica tree with an organic solvent or a fermented substance thereof as an active ingredient. CONSTITUTION:Small pieces of aloe and fruits of Japanese angelica tree are used as they are or ground and blended in the weight ratio of 1-99% and 99-1% (preferably 20-80% and 80-20%) to give 10 pts.wt. blend, which is immersed in 90-70 pts.wt. organic solvent (e.g. ethanol-water mixture) and kept at normal temperature to extract essence or the essence is preserved and fermented for about three months as it is to give a cosmetic containing the essence or the fermented substance thereof as an active ingredient. The cosmetic is applied to the affected part once or more daily to eliminate dandruff and falling hair, to produce black hair, to make the skin of the head part clean and to remove stains formed on the skin.
For both tasks, the training modalities are the same. After the pre-test, this group will have to mentally repeat the correct sequence as many times as possible, during 6 blocks of 30s. Then they will have to physically repeat the correct sequence as many times as possible, during 6 blocks of 30s. After this training, they will perform the post-test. And immediately after the post-test, they will receive the sham stimulation. The sham stimulation will be consisted of a gradual increase in current for 30 seconds until 1mA, immediately followed by gradual decrease for 30 s until 0mA.
AIMS: To investigate the relationship between cardiorespiratory fitness (CRF) and liver fat content (LFC) in community-based participants and highlight their relationship in people with different body mass indices (BMIs).
MATERIALS AND METHODS: Using UK Biobank data, CRF was estimated with bicycle ergometer fitness testing and was evaluated based on physical work capacity at 75% maximum heart rate (PWC75%). LFC was quantified through liver proton density fat fraction (PDFF) on magnetic resonance imaging. Multivariate linear regression models were used to analyse the associations of CRF and BMI with absolute reduction and percentage change in PDFF (%).
RESULTS: In total, 5765 participants with a mean age of 55.57 years and a median (range) follow-up of 10.7 (4.0-17.7) years were included. Compared with the lowest PWC75% tertile, the absolute reduction and percentage change in PDFF in the highest PWC75% tertile were -0.450 (95% confidence interval [CI] -0.699 to -0.192) and -4.152 (95% CI -6.044 to -2.104), respectively. These associations were independent of BMI, and individuals with obesity and normal weight had the largest absolute reduction and percentage change in LFC, respectively (p for interaction <0.001). Joint analysis showed that PWC75% and BMI had a negative dose-response relationship with PDFF. These associations were consistent in different sex and age subgroups (p for interaction >0.05).
CONCLUSIONS: There was a significant negative association between CRF and LFC, and this association was independent of BMI. The results of this study strongly recommend improving CRF to mitigate LFC.
OBJECTIVE: Poor medication adherence remains a concern for individuals managing their epilepsy with antiseizure medicines (ASMs); however, ethical concerns around withholding medication make it impossible to study the causal relationship between missed doses and seizures in patients. Previous preclinical studies from our group suggest that mechanistically distinct ASMs have varying degrees of forgiveness when a dose is missed. However, with only a few ASMs studied in the context of nonadherence, we sought to expand on previous work to understand the relationship between levetiracetam (LEV) nonadherence and breakthrough seizures.
METHODS: Chronic oral dosing was initiated in rats with established epilepsy via our automated medication-in-food delivery system coupled to 24/7 video-electroencephalographic recording. Baseline seizure burden was established for 4 weeks before enrolling subjects into a 4-week treatment period with LEV in a 100% fully adherent (75 mg/kg four times daily) or 50% variably adherent paradigm. The temporal relationship between missed doses and breakthrough seizures was correlated with LEV plasma and brain concentrations in separate cohorts of animals.
RESULTS: Full adherence to LEV significantly improved seizure control by 50% in half of the animals. Poor adherence worsened seizure frequency by 85%, with most rats having more severe seizures that formed in clusters following missed doses. LEV concentrations remained below therapeutic levels (<10 μg/mL) in nonadherent animals, with brain and plasma levels directly correlating with the degree of adherence in a 24-h period. Missed doses of LEV immediately increased the risk of breakthrough seizures; however, this risk was significantly reduced with improved adherence in a 24-h period.
SIGNIFICANCE: These findings enhance our understanding of ASM nonadherence in preclinical models, highlighting that the timing of missed doses and their impact on seizures may vary between different ASMs. Notably, LEV demonstrates a robust pharmacokinetic reliance on missed doses leading to breakthrough seizures.
The invention aims to prepare a collutory containing a thymol polyether complex. The collutory is characterized by being prepared from a thymol glycerol polyether complex, a menthol propylene glycol polyether complex, a nonionic surfactant coco-glucoside, glycerin, citric acid and purified water. The collutory has functions of killing and sterilizing staphylococcus aureus, escherichia coli, fungi, mycete and various microorganisms in the oral cavity of a human body. The collutory has multiple effects of sterilizing, cleaning, refreshing and comforting the oral cavity of the human body and the like, and can be used for inhibiting growth and propagation of oral bacteria, rapidly eliminating ozostomia caused by oral cavity factors and preventing oral ulcers, gingivitis, pulpitis and periodontal diseases. The collutory is in a light yellow transparent liquid in appearance, has a pleasant peppermint aroma and a pH value within 6 to 7, and is nontoxic and is nonirritating to the oral mucosa of the human body. When the collutory is used, the dilution concentration of the collutory is a concentration of 5% to 10% (volume).
FIELD: medicine. SUBSTANCE: method involves intravenously injecting blood plasma cryoprecipitates in addition to antibiotics in complex therapy. The cryoprecipitates are taken immediately after having been defrosted in the amount of 2-5 doses. A dose is 20-30 ml of cryoprecipitates large. The injected are given during 3-5 days. EFFECT: enhanced effectiveness of treatment.
Ciclopirox gel 0.77% contains a synthetic antifungal agent, ciclopirox USP. It is intended for topical dermatologic use only.

Each gram of ciclopirox gel contains 7.70 mg of ciclopirox USP in a gel consisting of carbomer homopolymer, isopropyl alcohol, and medium chain triglycerides, sodium hydroxide, sodium lauryl sulfate, and purified water.

Ciclopirox gel is a white, slightly fluid gel.

The chemical name for ciclopirox USP is 6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridinone, with the empirical formula C12H17NO2 and a molecular weight of 207.27. The CAS Registry Number is [29342-05-0]. The chemical structure is:
Immune checkpoint inhibitors, particularly PD-1/PD-L1 blockades, have been approved for unresectable hepatocellular carcinoma (HCC). However, high resistance rates still limit their efficacy, highlighting the urgent need to understand the underlying mechanisms and develop strategies for overcoming the resistance. In this study, tankyrasel binding protein 1 (TNKS1BP1) was found to interact with tripartite motif containing 21 (TRIM21) and mediated the ubiquitination of CCR4-NOT transcription complex subunit 4 (CNOT4) at the K239 residue via K48 and K6 linkage, which was essential for its tumorigenesis function. Autophagy and lipid reprogramming were identified as two possible mechanisms underlying the pro-tumor effect of TNKS1BP1. Upregulated TNKS1BP1 inhibited autophagy while induced lipid accumulation by inhibiting the JAK2/STAT3 pathway upon the degradation of CNOT4 in HCC. Importantly, knocking down TNKS1BP1 synergized with anti-PD-L1 treatment by upregulating PD-L1 expression on tumor cells via the JAK2/STAT3 pathway, and remodeling the tumor microenvironment by increasing infiltration of tumor-infiltrating lymphocytes as well as augmenting the effect of cytotoxic T lymphocytes. In conclusion, this study identified TNKS1BP1 as a predictive biomarker for patient prognosis and a promising therapeutic target to overcome anti-PD-L1 resistance in HCC.
Patients undergo radiotherapy to the tumor and lymph nodes, followed by a decrease in radiotherapy to the tumor alone. Radiation therapy is administered for a total of 5.5 weeks. Patients receive intravenous gemcitabine twice weekly over the first 3 weeks of radiotherapy. Cisplatin is administered intravenously twice weekly following gemcitabine therapy. Three patients are treated at each dose level. Dose escalation does not occur until all patients at a given dose level have completed radiotherapy and returned for a 4 week follow up. Patients exhibiting stable disease remain on therapy until disease progression or intolerable toxic effects. Patients experiencing toxic effects and no disease progression are retreated at a lower dose. Patients are followed every 3 months for the first 2 years then every 6 months for the next year.
A cocrystal of tiotropium bromide and lactose monohydrate is herein disclosed. In the cocrystal the components tiotropium bromide and lactose are preferably present in an almost stoichiometric ratio. Said cocrystal has a single endothermic event at about 191-3°C determined by DSC. A process for the preparation of the cocrystal is also disclosed. Preferably, the cocrystal has a particle size distribution of D90 < 10μ. The cocrystal is also disclosed for use as medicament, in particular for the treatment of a respiratory complaint, such as chronic obstructive pulmonary disease (COPD), bronchitis, emphysema and asthma.A pharmaceutical composition comprising the cocrystal as active ingredient is also disclosed, in particular for administration by inhalation. In the latter case, said cocrystal has a mean particle size of 0.5 to 10 µm, preferably 1 to 6 µm, more preferably 1.5 to 5 µm.
Renal ischemia/reperfusion (I/R) injury is a common clinical challenge faced by clinicians in kidney transplantation. I/R is the leading cause of acute kidney injury, and it occurs when blood flow to the kidney is interrupted and subsequently restored. I/R impairs renal function in both short and long terms. Renal ischemic preconditioning refers to all maneuvers intended to prevent or attenuate ischemic damage. In this context, the present review focuses on the dual-specificity phosphatase 3 (DUSP3), also known as vaccinia H1-related phosphatase, an uncommon regulator of mitogen-activated protein kinase (MAPK) phosphorylation. DUSP3 has different biological functions: (1) it acts as a tumor modulator and (2) it is involved in the regulation of immune response, thrombosis, hemostasis, angiogenesis, and genomic stability. These functions occur either through MAPK-dependent or MAPK-independent mechanisms. DUSP3 genetic deletion dampens kidney damage and inflammation caused by I/R in mice, suggesting DUSP3 as a potential target for preventing renal I/R injury. Here, we discuss the putative role of DUSP3 in ischemic preconditioning and the potential mechanisms of such an attenuated inflammatory response via improved kidney perfusion and adequate innate immune response.
BACKGROUND: With the recent surge in the utilization of electronic health records for cognitive decline, the research community has turned its attention to conducting fine-grained analyses of dementia onset using advanced techniques. Previous works have mostly focused on machine learning-based prediction of dementia, lacking the analysis of dementia progression and its associations with risk factors over time. The black box nature of machine learning models has also raised concerns regarding their uncertainty and safety in decision making, particularly in sensitive domains like healthcare.
OBJECTIVE: We aimed to characterize the progression of health conditions, such as chronic diseases and neuropsychiatric symptoms, of the participants in Mayo Clinic Study of Aging (MCSA) from initial mild cognitive impairment (MCI) diagnosis to dementia onset through network analysis.
METHODS: We used the data from the MCSA, a prospective population-based cohort study of cognitive aging, and examined the changing association among variables (i.e., participants' health conditions) from the first visit of MCI diagnosis to the visit of dementia onset using network analysis. The number of participants for this study are 97 with the number of visits ranging from 2 visits (30 months) to 7 visits (105 months). We identified the network communities among variables from three-fold collection of instances: (i) the first MCI diagnosis, (ii) progression to dementia, and (iii) dementia diagnosis. We determine the variables that play a significant role in the dementia onset, aiming to identify and prioritize specific variables that prominently contribute towards developing dementia. In addition, we explore the sex-specific impact of variables in relation to dementia, aiming to investigate potential differences in the influence of certain variables on dementia onset between males and females.
RESULTS: We found correlation among certain variables, such as neuropsychiatric symptoms and chronic conditions, throughout the progression from MCI to dementia. Our findings, based on patterns and changing variables within specific communities, reveal notable insights about the time-lapse before dementia sets in, and the significance of progression of correlated variables contributing towards dementia onset. We also observed more changes due to certain variables, such as cognitive and functional scores, in the network communities for the people who progressed to dementia compared to those who does not. Most changes for sex-specific analysis are observed in clinical dementia rating and functional activities questionnaire during MCI onset are followed by chronic diseases, and then by NPI-Q scores.
CONCLUSIONS: Network analysis has shown promising potential to capture significant longitudinal changes in health conditions, spanning from the MCI diagnosis to dementia progression. It can serve as a valuable analytic approach for monitoring the health status of individuals in cognitive impairment assessment. Furthermore, our findings indicate a notable sex difference in the impact of specific health conditions on the progression of dementia.
Patients will start with placebo in week 1 and cross over to Naltrexone in week 3. There will be a wash-out phase during week 2 using only moisturizer regularly and if necessary as rescue medications topical corticosteroids and/or antihistamines. The same rescue medications can be used during the following weeks of the cross-over treatment. At visit 2 and 4 patients will be asked the area where they are experiencing most intense itch and we will take there suction blisters (preferably on the trunk). Suction blisters will be taken after week 1 (1 week on treatment arm 1) and after week 3 (1 week on treatment arm 2).
PURPOSE:To obtain a photochemical medicine for cancers, comprising a pyrylium-based compound as an active ingredient. CONSTITUTION:This photochemical medicine contains a compound of the formula (ring X is a heterocyclic ring, X is O, S, Se or Te and ring X is a pyrylium ring or a pyrylium analog ring; R<1> and R<2> each is H, a halogen, sulfonate, amino, styryl, nitro, hydroxyl, etc.; R<3> is A or L-A; L is (CH=CH), a bifunctional group derived from an aryl, etc.; A is an aryl, etc.; Y<-> is an anion). The photochemical medicine is a medicine of a completely different type from an existing porphyrin-based medicine. The compound of the formula or its salt has excellent penetration to organism tissue and can effectively treat. Light rays having 600-1,000nm long wavelength can be used as treating irradiation light and have a high light absorption intensity. In the case of an injection, 0.1-10mg/ml of the compound of the formula is mixed with a solvent. In the case of an oral agent, 1-50wt.% of the compound of the formula is contained and pharmaceutically manufactured.
The method for treating alcohol addiction provides for the basic therapy comprising suggestive psychotherapy and homeopathy. AlkoZAP1 homeopathic preparation used for this purpose comprises Selenium 6C, Nux vomica 6C, Carbo vegit. 3C, Qvercus 3C. The preparation is taken sublingually, 5-7 grains, 30 minutes before the meals. The homeopathy is provided after the primary suggestive psychotherapy or in the setting of suggestive psychotherapy. In 25-28 days, 7-10-days interval follows. Then the course of the treatment is repeated until the elimination of alcohol addiction.
Each participant will be treated with a vehicle cream qd for the other half of the face for 1 month. In the second month all patients will be treated with ivermectin cream for the entire skin involvement.
Fibromyalgia is a potentially disabling idiopathic disease characterized by widespread chronic pain associated with comorbidities such as fatigue, anxiety, and depression. Current therapeutic approaches present adverse effects that limit adherence to therapy. Diosmetin, an aglycone of the flavonoid glycoside diosmin found in citrus fruits and the leaves of Olea europaea L., has antinociceptive, anti-inflammatory, and antioxidant properties. Here, we investigated the effect of diosmetin on nociceptive behaviors and comorbidities in an experimental fibromyalgia model induced by reserpine in mice. To induce the experimental fibromyalgia model, a protocol of subcutaneous injections of reserpine (1 mg/kg) was used once a day for three consecutive days in adult male Swiss mice. Mice received oral diosmetin on the fourth day after the first reserpine injection. Nociceptive (mechanical allodynia, muscle strength, and thermal hyperalgesia) and comorbid (depressive-like and anxiety behavior) parameters were evaluated. Potential adverse effects associated with diosmetin plus reserpine (locomotor alteration, cataleptic behavior, and body weight and temperature changes) were also evaluated. Oral diosmetin (0.015-1.5 mg/kg) reduced the mechanical allodynia, thermal hyperalgesia, and loss of muscle strength induced by reserpine. Diosmetin (0.15 mg/kg) also attenuated depressive-like and anxiety behaviors without causing locomotor alteration, cataleptic behavior, and alteration in weight and body temperature of mice. Overall, diosmetin can be an effective and safe therapeutic alternative to treat fibromyalgia symptoms, such as pain, depression and anxiety.
OBJECTIVE: Initiatives, "Every Newborn Action Plans" and "Sustainable Developmental Goals," are profoundly shaping global infant mortality trends. Concurrently, professional organizations recommended curricula to prevent extreme hyperbilirubinemia (EHB) sequelae. Therefore we assessed if these efforts have successfully decreased EHB-related mortality over time.
STUDY DESIGN: We used the Global Burden of Diseases 2019 database to determine neonatal and infant mortality and the burden of kernicterus from 1990-2019.
RESULTS: Globally, kernicterus accounted for 2.8 million infant deaths and trended downwards significantly from 1990 to 2019. By 2019, kernicterus-related mortality was 4 and 293 per million livebirths in high (HICs) and low income countries (LICs), respectively. 82% of deaths occurred in LICs and lower-middle income-countries. Average declines of mortality rates were 6.2% and 3.0% for HICs and LICs, respectively.
CONCLUSIONS: Kernicterus-related mortality has been effectively reduced to <5 per million in HICs. Skills and knowledge transfer can potentially transform frontline services to bridge discordant kernicteric outcomes worldwide.
Eligible patients with refractory FCP will be randomized to one of 2 arms: the active treatment group, who will receive the HHT program; or a control group. Patients in the active treatment group will receive the 12-week digital audio HHT program. This protocol consists of 7 sessions, each approximately 30-40 minutes, administered every 2 weeks, for a cumulative 12 weeks of treatment, along with a shorter (approximately 12 minute) session administered daily. Patients in the control group will receive a digital audio educational program. Subjects in both groups will be assessed at baseline, 4-6 weeks into treatment, at the end of the treatment, and 3 months after conclusion of the program. Global change in symptoms will be assessed with a 7-point Likert scale. Patients will be considered to respond if they have significant improvement on the Likert scale at the post-treatment visit. Patients will complete a chest pain symptom diary, the SCL-90 and the Coping Strategies Questionnaire-Catastrophizing subscale to assess psychological features, and the SF-36 as a measure of Health Related Quality of Life (HRQOL).
The present invention relates to an environmentally-friendly water tissue composition, and a method for producing the same. The water tissue composition uses herbal medicinal materials such as burnt alum, licorice, and edible sulfur and saline solution to prevent and alleviate skin inflammation and help to remove smells, and also uses a natural preservative. The water tissue composition is mixed with 13-18 wt% of burnt alum, 4-10 wt% of licorice liquid, 70-81 wt% of saline solution, and 2-8 wt% of edible sulfur without generating a precipitate. The water tissue composition maintains hygiene and removes smells after excretion or before, during, and after female menses. The water tissue composition has a low irritation inflammation alleviating function with respect to hemorrhoid. The water tissue composition removes smells from sweating an axilla or groin region. The water tissue composition can clean out contaminants in a wounded part when a person is wound during mount-climbing or fishing or a child is wounded. The water tissue composition can also alleviate inflammation caused by a disposable diaper of an infant.
<P>PROBLEM TO BE SOLVED: To provide a new polypeptide having a PDE (phosphodiesterase) activity, a DNA encoding the PDE polypeptide and medicines for diagnosis, prophylaxis or therapy of diabetes, ischemic heart diseases, hypertension, nephritis, pancreatitis, ulcer, allergy, asthma, rheumatism, osteoporosis, pain, anxiety, schizophrenia, manic-depressive psychosis, Parkinson's disease, dementia, infectious diseases, malignant tumor, etc., by utilizing the DNA or an antibody recognizing the polypeptide.  <P>SOLUTION: The new polypeptide has the PDE activity. A method for producing the polypeptide and the DNA encoding the polypeptide are provided. A recombinant vector is obtained by integrating the DNA. A transformant carries the recombinant vector. The antibody recognizes the polypeptide. A method for determining the polypeptide and an immunostaining method use the antibody. A method for screening substances varying the expression of a gene encoding the polypeptide is provided. The medicines, etc., for diagnosis, prophylaxis or therapy of diseases such as diabetes, encephalopathy, renopathy or cancer using the DNA or antibody are provided.  <P>COPYRIGHT: (C)2005,JPO&NCIPI